# A Study of DCR-STAT3 in Adults With Solid Tumors

> **NCT06098651** · PHASE1 · COMPLETED · sponsor: **Dicerna Pharmaceuticals, Inc., a Novo Nordisk company** · enrollment: 26 (actual)

## Conditions studied

- Solid Tumor, Adult
- Refractory Tumor

## Interventions

- **DRUG:** DCR-STAT3

## Key facts

- **NCT ID:** NCT06098651
- **Lead sponsor:** Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-14
- **Primary completion:** 2025-09-17
- **Final completion:** 2025-09-17
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06098651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06098651, "A Study of DCR-STAT3 in Adults With Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06098651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*